First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback